Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
IPO Year: 2020
Exchange: NASDAQ
Website: calliditas.se
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2023 | $60.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $18.00 | Neutral | Guggenheim |
| 12/20/2021 | $52.00 → $62.00 | Buy | HC Wainwright & Co. |